This week’s Oncology update highlights regulatory approvals, access milestones, clinical progress, and advancing treatment options across multiple biomarker-defined cancers.
In Today’s Newsletter
Dive deeper
💊 Braftovi first-line mCRC EC approval [1] [EU • 22 Jun 2026]
https://www.prnewswire.com/news-releases/laboratoires-pierre-fabre-receives-european-commission-approval-for-braftovi-encorafenib-in-combination-with-cetuximab-and-folfox-fluorouracil-leucovorin-and-oxaliplatin-for-the-first-line-treatment-of-adult-patients-with-b-302806336.html
Context: BREAKWATER evaluated Braftovi (encorafenib) plus cetuximab and mFOLFOX6 in previously untreated BRAFV600E-mutant mCRC.
Key point: EC approved Braftovi plus cetuximab and FOLFOX for first-line adult BRAFV600E-mutant metastatic colorectal cancer.
Implication: May influence prescriber choice and payer reviews pending full data.
🧬 Tecelra full FDA approval and pediatric expansion [2] [US • 22 Jun 2026]
https://www.prnewswire.com/news-releases/us-worldmeds-receives-full-us-fda-approval-of-tecelra-afamitresgene-autoleucel-with-an-expanded-indication-extending-the-first-approved-engineered-t-cell-therapy-for-a-solid-tumor-to-children-as-young-as-12-302806599.html
Context: SPEARHEAD-1 included 137 patients with unresectable or metastatic synovial sarcoma and biomarker eligibility.
Key point: FDA granted full approval for Tecelra (afamitresgene autoleucel) and expanded use to patients 12 years and older.
Implication: May influence prescriber choice and payer reviews pending full data.
🎯 Iza-bren first China approval in nasopharyngeal carcinoma [3] [China • 22 Jun 2026]
https://systimmune.com/news_detail/49
Context: BL-B01D1-303 studied iza-bren (BL-B01D1), an EGFR×HER3 bispecific ADC, in recurrent or metastatic NPC.
Key point: China’s CDE approved iza-bren for NPC after prior platinum-based chemotherapy and PD-1/PD-L1 inhibitor therapy.
Implication: May influence prescriber choice and payer reviews pending full data.
🫁 Zepzelca Japan NDA in first-line SCLC maintenance [4] [Japan • 23 Jun 2026]
https://pharmamar.com/en/pharmamars-partner-merck-has-submitted-a-new-drug-application-in-japan-for-zepzelca-lurbinectedin-regarding-first-line-maintenance-therapy-in-small-cell-lung-cancer/
Context: PharmaMar and Merck have a Japan licensing agreement for lurbinectedin in SCLC.
Key point: Merck submitted a Japan NDA for Zepzelca (lurbinectedin) in first-line maintenance SCLC, with priority review.
Implication: Introduces competition that may affect pricing and formulary access.
🇨🇦 Itovebi completes pCPA negotiations in Canada [5] [Canada • 23 Jun 2026]
https://www.rochecanada.com/media/roche-canada-and-the-pan-canadian-pharmaceutical-alliance-pcpa-have-successfully-completed-negotiations-for-itovebi-inavolisib-a-targeted-treatment-for-advanced-hormone-receptor-positive-her2-negative-breast-cancer-with-a-pik3ca-mutation
Context: Itovebi (inavolisib) is used with palbociclib and fulvestrant in endocrine-resistant, PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer.
Key point: Roche Canada completed pCPA negotiations for Itovebi, a step toward public access across Canadian jurisdictions.
Implication: May expand screening, initiation, and follow-up at scale.
🧫 Padcev plus Keytruda EC perioperative MIBC approval [6] [EU • 24 Jun 2026]
https://newsroom.astellas.com/2026-06-24-european-commission-approves-padcev-enfortumab-vedotin-in-combination-with-keytruda-pembrolizumab-as-the-first-and-only-approved-perioperative-treatment-option-for-cisplatin-ineligible-patients-with-resectable-muscle-invasive-bladder-cancer
Context: EV-303 evaluated perioperative enfortumab vedotin plus pembrolizumab versus surgery alone in cisplatin-ineligible or cisplatin-declining MIBC.
Key point: EC approved Padcev plus Keytruda as neoadjuvant and adjuvant therapy for cisplatin-ineligible resectable MIBC.
Implication: May influence prescriber choice and payer reviews pending full data.
🌸 Trodelvy FDA approval in first-line metastatic TNBC [7] [US • 24 Jun 2026]
https://www.gilead.com/news/news-details/2026/u-s–fda-approves-trodelvy-for-first-line-treatment-of-metastatic-triple-negative-breast-cancer
Context: ASCENT-03 and ASCENT-04 evaluated Trodelvy-based regimens in first-line metastatic TNBC.
Key point: FDA approved Trodelvy (sacituzumab govitecan-hziy) as monotherapy or with Keytruda, depending on PD-L1 status and immunotherapy eligibility.
Implication: May influence prescriber choice and payer reviews pending full data.
🫁 Serplulimab EC approval in first-line sqNSCLC [8] [EU • 26 Jun 2026]
https://www.henlius.com/en/NewsDetails-6005-26.html
Context: ASTRUM-004 evaluated serplulimab plus chemotherapy in previously untreated locally advanced or metastatic sqNSCLC.
Key point: EC approved serplulimab (Hetronifly) plus chemotherapy for first-line unresectable locally advanced or metastatic sqNSCLC.
Implication: May influence prescriber choice and payer reviews pending full data.
🦠 RP1 BLA resubmission accepted for advanced melanoma [9] [US • 26 Jun 2026]
https://ir.replimune.com/news-releases/news-release-details/replimune-announces-fda-acceptance-rp1-biologics-license
Context: IGNYTE evaluated RP1 (vusolimogene oderparepvec) plus nivolumab after confirmed progression on anti-PD-1-containing therapy.
Key point: FDA accepted Replimune’s RP1 BLA resubmission for advanced melanoma as a complete class 1 response.
Implication: Introduces competition that may affect pricing and formulary access.
🎯 Datroway CHMP positive opinion in first-line metastatic TNBC [10] [EU • 26 Jun 2026]
https://www.astrazeneca.com/media-centre/press-releases/2026/datroway-recommended-for-approval-in-eu-for-tnbc.html
Context: TROPION-Breast02 evaluated Datroway (datopotamab deruxtecan) versus chemotherapy in previously untreated metastatic TNBC not eligible for immunotherapy.
Key point: CHMP recommended Datroway monotherapy for first-line adult unresectable or metastatic TNBC in patients not candidates for PD-1/PD-L1 therapy.
Implication: May influence prescriber choice and payer reviews pending full data.
Why it matters
- ADCs are moving earlier across major tumors, including colorectal cancer, bladder cancer, TNBC, and nasopharyngeal carcinoma. [1], [3], [6], [7], [10]
- First-line metastatic TNBC is becoming more segmented by PD-L1 status and immunotherapy eligibility. [7], [10]
- Perioperative oncology remains active, with Padcev plus Keytruda expanding into curative-intent MIBC in Europe. [6]
- Access and review milestones can shift availability before broad reimbursement, as seen with Itovebi in Canada and Zepzelca in Japan. [4], [5]
- Biomarker-defined labels continue to shape uptake, including BRAFV600E, HLA and MAGE-A4, PIK3CA, PD-L1, and TROP2. [1], [2], [5], [7], [10]
📚 Discover the full Oncology archive on our research hub page.
🚀 Accelerate your success. Contact us now
📂 Explore our case studies. See examples of our work.
💡 Read our insights. Learn from our latest reports and analysis
🎬 Watch on YouTube. Subscribe and never miss a video.
🧰 See our full range of services. Discover how we can help you.
FAQ
What did the EC approve for Braftovi in colorectal cancer?
The EC approved Braftovi (encorafenib) plus cetuximab and FOLFOX for first-line adult BRAFV600E-mutant metastatic colorectal cancer. The source cites BREAKWATER as the supporting Phase 3 trial. [1]
Which Tecelra patients are now covered after FDA full approval?
Tecelra is approved for adults and pediatric patients 12 years and older with unresectable or metastatic synovial sarcoma after prior chemotherapy, if HLA and MAGE-A4 eligibility criteria are met. [2]
What is notable about iza-bren’s China approval?
SystImmune says this is the first regulatory approval for iza-bren (BL-B01D1), an EGFR×HER3 bispecific ADC. The label covers recurrent or metastatic NPC after prior platinum and PD-1/PD-L1 therapy. [3]
What is the status of Zepzelca in Japan?
Merck submitted a Japan NDA for Zepzelca (lurbinectedin) in first-line maintenance SCLC. The application received priority review, according to PharmaMar. [4]
How do Trodelvy and Datroway differ in first-line metastatic TNBC positioning?
Trodelvy received FDA approval across PD-L1 status, as monotherapy or with Keytruda depending on PD-L1 status. Datroway received a CHMP recommendation for EU patients not candidates for PD-1/PD-L1 therapy. [7], [10]
What is the next FDA milestone for RP1?
FDA accepted Replimune’s RP1 BLA resubmission for advanced melanoma, with a goal date of 02 Aug 2026 and an advisory committee meeting expected in late Jul 2026. [9]
Entities / Keywords
Braftovi, encorafenib, cetuximab, FOLFOX, mFOLFOX6, BRAFV600E-mutant mCRC, BREAKWATER, Pierre Fabre
Tecelra, afamitresgene autoleucel, engineered T-cell therapy, synovial sarcoma, HLA-A*02, MAGE-A4, SPEARHEAD-1, US WorldMeds
Iza-bren, BL-B01D1, EGFR×HER3 bispecific ADC, nasopharyngeal carcinoma, NPC, BL-B01D1-303, SystImmune, Biokin
Zepzelca, lurbinectedin, small cell lung cancer, SCLC, first-line maintenance, PharmaMar, Merck, MHLW
Itovebi, inavolisib, PIK3CA-mutated breast cancer, HR-positive, HER2-negative, pCPA, Roche Canada
Padcev, enfortumab vedotin, Keytruda, pembrolizumab, MIBC, EV-303, KEYNOTE-905, Astellas
Trodelvy, sacituzumab govitecan, Trop-2 ADC, mTNBC, ASCENT-03, ASCENT-04, Gilead
Serplulimab, Hetronifly, anti-PD-1, sqNSCLC, ASTRUM-004, Henlius
RP1, vusolimogene oderparepvec, oncolytic immunotherapy, HSV-1, nivolumab, melanoma, IGNYTE, Replimune
Datroway, datopotamab deruxtecan, TROP2-directed ADC, TROPION-Breast02, AstraZeneca, Daiichi Sankyo
References
- https://www.prnewswire.com/news-releases/laboratoires-pierre-fabre-receives-european-commission-approval-for-braftovi-encorafenib-in-combination-with-cetuximab-and-folfox-fluorouracil-leucovorin-and-oxaliplatin-for-the-first-line-treatment-of-adult-patients-with-b-302806336.html
- https://www.prnewswire.com/news-releases/us-worldmeds-receives-full-us-fda-approval-of-tecelra-afamitresgene-autoleucel-with-an-expanded-indication-extending-the-first-approved-engineered-t-cell-therapy-for-a-solid-tumor-to-children-as-young-as-12-302806599.html
- https://systimmune.com/news_detail/49
- https://pharmamar.com/en/pharmamars-partner-merck-has-submitted-a-new-drug-application-in-japan-for-zepzelca-lurbinectedin-regarding-first-line-maintenance-therapy-in-small-cell-lung-cancer/
- https://www.rochecanada.com/media/roche-canada-and-the-pan-canadian-pharmaceutical-alliance-pcpa-have-successfully-completed-negotiations-for-itovebi-inavolisib-a-targeted-treatment-for-advanced-hormone-receptor-positive-her2-negative-breast-cancer-with-a-pik3ca-mutation
- https://newsroom.astellas.com/2026-06-24-european-commission-approves-padcev-enfortumab-vedotin-in-combination-with-keytruda-pembrolizumab-as-the-first-and-only-approved-perioperative-treatment-option-for-cisplatin-ineligible-patients-with-resectable-muscle-invasive-bladder-cancer
- https://www.gilead.com/news/news-details/2026/u-s–fda-approves-trodelvy-for-first-line-treatment-of-metastatic-triple-negative-breast-cancer
- https://www.henlius.com/en/NewsDetails-6005-26.html
- https://ir.replimune.com/news-releases/news-release-details/replimune-announces-fda-acceptance-rp1-biologics-license
- https://www.astrazeneca.com/media-centre/press-releases/2026/datroway-recommended-for-approval-in-eu-for-tnbc.html